Karen G Montgomery

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study
    Karen G Montgomery
    Victorian Breast Cancer Research Consortium, Cancer Genetics Laboratory, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Breast Cancer Res 6:R390-4. 2004
  2. ncbi The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Centre, St, Andrews Place, East Melbourne, Victoria, Australia
    Breast Cancer Res 7:R353-6. 2005
  3. ncbi The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Cancer Epidemiol Biomarkers Prev 12:1109-11. 2003
  4. ncbi Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus
    Wayne A Phillips
    Surgical Oncology Laboratory, Peter MacCallum Cancer Centre, and Department of Surgery St Vincent s Hospital, University of Melbourne, Parkville, Vic, Australia
    Int J Cancer 118:2644-6. 2006
  5. ncbi Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors
    Anjali Tikoo
    Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    PLoS ONE 7:e36924. 2012
  6. ncbi Mutation of the PIK3CA gene in ovarian and breast cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Res 64:7678-81. 2004
  7. ncbi An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
    Kathryn M Kinross
    Cancer Research Division, Peter MacCallum Cancer Centre Peter Mac, East Melbourne, Victoria, Australia
    J Clin Invest 122:553-7. 2012

Collaborators

Detail Information

Publications7

  1. ncbi The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study
    Karen G Montgomery
    Victorian Breast Cancer Research Consortium, Cancer Genetics Laboratory, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Breast Cancer Res 6:R390-4. 2004
    ....
  2. ncbi The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Centre, St, Andrews Place, East Melbourne, Victoria, Australia
    Breast Cancer Res 7:R353-6. 2005
    ..It contains a glutamine repeat (CAG/CAA) polymorphism at its carboxyl-terminal region that may alter the transcriptional activation of the receptor and affect susceptibility to breast cancer through altered sensitivity to hormones...
  3. ncbi The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years
    Karen G Montgomery
    Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Cancer Epidemiol Biomarkers Prev 12:1109-11. 2003
    ..3-6.2; P = 0.005), gave the best fit under parsimony. Although the biological role of the I655V polymorphism is not known, large independent studies of early onset breast cancer are warranted to attempt to replicate this finding...
  4. ncbi Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus
    Wayne A Phillips
    Surgical Oncology Laboratory, Peter MacCallum Cancer Centre, and Department of Surgery St Vincent s Hospital, University of Melbourne, Parkville, Vic, Australia
    Int J Cancer 118:2644-6. 2006
    ....
  5. ncbi Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors
    Anjali Tikoo
    Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    PLoS ONE 7:e36924. 2012
    ....
  6. ncbi Mutation of the PIK3CA gene in ovarian and breast cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Res 64:7678-81. 2004
    ..5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Our study is the first direct evidence that PIK3CA is an oncogene in ovarian cancer and greatly extends recent findings in breast cancer...
  7. ncbi An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
    Kathryn M Kinross
    Cancer Research Division, Peter MacCallum Cancer Centre Peter Mac, East Melbourne, Victoria, Australia
    J Clin Invest 122:553-7. 2012
    ..These results demonstrate that the Pik3caH1047R mutation with loss of Pten is enough to promote ovarian cell transformation and that we have developed a model system for studying possible therapies...